Active ingredients: zoledronic acid
What it is used for
Treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures. Treatment of osteoporosis in patients over 50 years of age with a history of at least one low trauma hip fracture, to reduce the incidence of further fractures. To increase bone mineral density in men with osteoporosis. To increase bone mineral desity in patients with osteoporosis associated with long term glucocorticoid use. To prevent glucocorticoid-induced bone mineral density loss. Treatment of Paget's disease of bone.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store below 30 degrees Celsius
- Shelf lifetime is 18 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Clear to colourless solution for infusion free from visible particulates in a PP bag with 1 tube, a twist-off administration cap and clear overwrap.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2019. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient zoledronic acid
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems